SCHEMBL1421817

SCHEMBL1421817

Cc1cccc2c(C(CCCC#N)c3ccc(C(F)(F)F)cc3)c[nH]c12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.36
CYP19A1 P11511 4/20 0.35
SOS2 Q07890 1/20 0.34
HTR2A P28223 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
HDAC9 Q9UKV0 1/20 0.33
HDAC5 Q9UQL6 1/20 0.33
MAPT P10636 2/20 0.33
SLC6A4 P31645 2/20 0.33
CYP2D6 P10635 1/20 0.33
SLC6A2 P23975 1/20 0.33
KCNH2 Q12809 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1423731 0.95 AR (0.36) ARCYP19A1SOS2HTR2AMAPT
SCHEMBL12397654 0.88 MGAM (0.39) ARCYP19A1SOS2HTR2AHDAC3
SCHEMBL1422927 0.88 ALDH1A1 (0.35) CYP19A1HDAC3HDAC4HDAC1HDAC7
SCHEMBL1423209 0.87 DYRK1A (0.40) CYP19A1HDAC3HDAC4HDAC1HDAC7
SCHEMBL1423259 0.87 CYP19A1 (0.37) CYP19A1HDAC3HDAC4HDAC1HDAC7
SCHEMBL1423240 0.87 AR (0.37) ARCYP19A1SOS2HTR2AHDAC3
SCHEMBL21399853 0.85 HTR2A (0.46) ARCYP19A1SOS2HTR2AMAPT
SCHEMBL1422888 0.84 SOS2 (0.40) ARCYP19A1SOS2HTR2AMAPT
SCHEMBL1423442 0.83 KDM4E (0.36) ARCYP19A1SLC6A4CYP2D6SLC6A2
SCHEMBL1422696 0.83 NR3C1 (0.42) ARNR3C1PGRNR3C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110183928-A1 3-Cyanoalkyl- and 3-hydroxyalkylindoles and use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-07-28 US disclosed
EP-2297099-A1 3-CYANOALKYL- AND 3-HYDROXYALKYLINDOLES AND USE THEREOF Bayer Schering Pharma Aktiengesellschaft (DE) 2011-03-23 EP disclosed
WO-2009156091-A1 3-CYANOALKYL- AND 3-HYDROXYALKYLINDOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-12-30 WO disclosed
WO-2009156091-A1 3-CYANOALKYL- AND 3-HYDROXYALKYLINDOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183928-A1 3-Cyanoalkyl- and 3-hydroxyalkylindoles and use thereof HTR3C, HTR3A, ADRB3 AR 4230/4885CYP19A1 3150/4885SOS2 2831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.